市場調査レポート
商品コード
1063201
細胞解離の世界市場:2021~2028年Global Cell Dissociation Market - 2021-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
細胞解離の世界市場:2021~2028年 |
出版日: 2022年03月03日
発行: DataM Intelligence
ページ情報: 英文 175 Pages
納期: 約2営業日
|
当レポートでは、世界の細胞解離市場について調査分析し、市場力学、COVID-19分析、製品タイプ・組織・エンドユーザー・地域別市場分析、競合情勢、企業プロファイルを提供しています。
The global cell dissociation market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
The cell dissociation process is also called Trypsinization. With the help of proteolytic enzymes, the adhering cell is separated from the surface or substrate. Cell dissociation cushions, which detach cell lines and tissues from containers' plastic or glass surfaces for increasing isolation efficacy with high cell practicality, have collagenolytic and proteolytic properties.
The increasing R&D activities in biopharmaceutical companies are expected to drive market growth.
The biopharmaceutical industry's major firms are focusing on R&D in various therapeutic areas to bring novel pharmaceuticals to market. These businesses are doing so by investing substantially in clinical trials, efficacy studies, and toxicity studies, among other things. The vast majority of this research utilizes tissue dissociation products to isolate cells from primary tissues. For instance, The pharmaceutical sector spent $83 billion on research and development in 2019. Compared to the preceding decade, the number of new pharmaceuticals licensed for sale increased by 60% between 2010 and 2019, reaching a high of 59 new drugs approved in 2018.
Moreover, America's biopharmaceutical companies are committed to advancing personalized medicines. A recent industry survey revealed that 42% of new medicines in the pipeline could be personalized medicines. Additionally, Researchers and scientists are building on a huge body of knowledge that has gathered through time as they examine novel substances, illuminating illness pathways and providing insight into the best medication targets. Thus, the market is expected to drive in the forecast period.
The high cost of tissue and cell-based procedures, enzyme-free dissociation products are preferred over enzymatic dissociation products, ethical limits and concerns about the use of cell-based research and lack of infrastructure for cell-based research in developing regions are some of the factors due to which the market is expected to get hampered in the forecast period.
The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic has provided crucial growth prospects. The amount of research and development to study and evaluate the virus that triggered the pandemic has doubled. Therefore, the market is likely to grow faster in developed nations with many research organizations. Countries in the Asia Pacific and other emerging regions, on the other hand, have increased their research on the new coronavirus.
In contrast, the COVID-19 pandemic has had a substantial impact on hospital resources worldwide. It has largely been accomplished by drastically lowering inpatient and outpatient services for various diseases and instituting infection prevention and control methods. The frequency of cancer screening and diagnostic treatments dropped dramatically, with the epidemic affecting countries worldwide. Thus, the market will undergo impetus growth during the forecast period.
The enzymatic dissociation products segment is expected to dominate in 2020. Enzymatic dissociation is a method of disaggregating cell culture samples using particular proteins. The procedure uses enzymes such as trypsin and collagenase to break down tissue and release the target cells. The tissue type determines the enzyme used, and finding the optimum mix produces the best results. Moreover, enzymes are used in stem cell research and cell biology investigations for cell and tissue dissociation, primary cell separation, and single-cell harvesting. The employment of enzymes for cell dissociation is very common. Any dissociation procedure aims to get as many functionally viable dissociated cells as possible. The kind of tissue, age of the animal/human, dissociation media utilized, an enzyme used, enzyme concentration, temperature, and genetic alterations all influence the outcome of any dissociation operation. As a result, numerous enzymes are used in research for various applications. Trypsin, collagenase, elastase, and hyaluronidase are among the most commonly employed enzymatic dissociation products in decreasing the frequency of use. Thus, the market segment is expected to boost in the forecast period from the above statements.
In 2020, North America accounted for the highest revenue share. Sustained expansion in the pharmaceutical and biotechnology sectors, rising cancer and other chronic illness incidences, and a strong trend of R&D investments in life sciences by industry and academia, acquisition and collaboration by the key players in the region are some of the factors due to which the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. In contrast, in 2020, an estimated 1,806,590 new cancer cases were diagnosed in the United States, and 606,520 people died from the disease. The three most common cancers for women are breast, lung, and colorectal, and they will account for an estimated 50% of all new cancer diagnoses in 2020.
Moreover, in 2020, Thermo Fisher Scientific extended its strategic relationship with Symphogen (Denmark) to promote biopharmaceutical discovery and development. Thermo Fisher Scientific acquired QIAGEN N.V. (Germany) to extend its Specialty Diagnostics range. Therefore, it has increased the demand for cell dissociation products in the region. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Major key players in the cell dissociation market are: Merck KGaA, Thermo Fisher Scientific, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Miltenyi Biotec, PromoCell GmbH, AcceGen, Capricorn Scientific, Neuromics and Genlantis.
Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Gibco: Gibco Cell Dissociation Buffer is a membrane-filtered, isotonic, and enzyme-free solution of salts, chelating agents, and cell-conditioning agents in calcium-free and magnesium-free phosphate-buffered saline (PBS).
The global cell dissociation market report would provide an access to an approx. 45+ market data table, 40+ figures and 175 pages.
LIST NOT EXHAUSTIVE